MX2020012176A - Derivado policiclico de carbamoilpiridona. - Google Patents

Derivado policiclico de carbamoilpiridona.

Info

Publication number
MX2020012176A
MX2020012176A MX2020012176A MX2020012176A MX2020012176A MX 2020012176 A MX2020012176 A MX 2020012176A MX 2020012176 A MX2020012176 A MX 2020012176A MX 2020012176 A MX2020012176 A MX 2020012176A MX 2020012176 A MX2020012176 A MX 2020012176A
Authority
MX
Mexico
Prior art keywords
sup
polycyclic carbamoylpyridone
carbamoylpyridone derivative
ring
substituted
Prior art date
Application number
MX2020012176A
Other languages
English (en)
Inventor
Yoshiyuki Taoda
Yuto UNOH
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2020012176A publication Critical patent/MX2020012176A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con un compuesto representado por la Fórmula (I). (En la fórmula, el anillo A es un heterociclo sustituido o no sustituido; el anillo C es un anillo de benceno o similar; R1 es halógeno o similar; R2a y R2b son cada uno independientemente hidrógeno o similares; R3 es alquilo sustituido o no sustituido o similar; R4 es hidrógeno o similar; y n es un número entero de 1 a 3).
MX2020012176A 2018-05-31 2019-05-30 Derivado policiclico de carbamoilpiridona. MX2020012176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018104156 2018-05-31
PCT/JP2019/021446 WO2019230858A1 (ja) 2018-05-31 2019-05-30 多環性カルバモイルピリドン誘導体

Publications (1)

Publication Number Publication Date
MX2020012176A true MX2020012176A (es) 2021-01-29

Family

ID=68698918

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012176A MX2020012176A (es) 2018-05-31 2019-05-30 Derivado policiclico de carbamoilpiridona.
MX2023010377A MX2023010377A (es) 2018-05-31 2020-11-13 Derivado policiclico de carbamoilpiridona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010377A MX2023010377A (es) 2018-05-31 2020-11-13 Derivado policiclico de carbamoilpiridona.

Country Status (22)

Country Link
US (2) US11649236B2 (es)
EP (2) EP3805220A4 (es)
JP (2) JP7328962B2 (es)
KR (1) KR20210015922A (es)
CN (2) CN112513042B (es)
AR (1) AR115455A1 (es)
AU (2) AU2019277548B2 (es)
BR (1) BR112020024077A2 (es)
CA (1) CA3102063A1 (es)
CL (1) CL2020003002A1 (es)
CO (1) CO2020014294A2 (es)
CR (2) CR20230571A (es)
DO (1) DOP2020000221A (es)
EA (1) EA202092921A1 (es)
IL (1) IL279051A (es)
MA (1) MA52795A (es)
MX (2) MX2020012176A (es)
PE (1) PE20210477A1 (es)
PH (1) PH12020552000A1 (es)
SG (1) SG11202011382PA (es)
WO (1) WO2019230858A1 (es)
ZA (1) ZA202007567B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
US20230058677A1 (en) * 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
WO2021107066A1 (ja) * 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗hiv薬を組み合わせることを特徴とするhiv感染症の予防及び治療用医薬
AU2021225809B2 (en) 2020-02-24 2023-08-24 Gilead Sciences, Inc. Tetracyclic compounds for treating HIV infection
CN115667270B (zh) * 2020-05-21 2024-06-04 辰欣药业股份有限公司 稠环衍生物及其在药学上的应用
MX2023001194A (es) * 2020-07-27 2023-04-20 Merck Sharp & Dohme Llc Inhibidores de la endonucleasa policiclicos dependientes de la capside para el tratamiento o la prevencion de la influenza.
FI4196479T3 (fi) 2021-01-19 2024-01-17 Gilead Sciences Inc Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä
CN117751118A (zh) * 2021-07-30 2024-03-22 吉斯凯(苏州)制药有限公司 大环吡啶酮类化合物及其应用
WO2024061257A1 (zh) * 2022-09-20 2024-03-28 吉斯凯(苏州)制药有限公司 多环氮杂环酮类化合物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
EP1578748B1 (en) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
KR101504998B1 (ko) 2005-04-28 2015-03-23 비이브 헬쓰케어 컴퍼니 Hiv 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
KR20080064182A (ko) 2005-10-27 2008-07-08 시오노기세야쿠 가부시키가이샤 Hiv 인테그라아제 억제활성을 가지는 다환성카르바모일피리돈 유도체
SG183484A1 (en) 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
BR112014008896A2 (pt) 2011-10-12 2017-04-18 Shionogi & Co derivado de piridona policíclico tendo atividade inibidora de integrase
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
RS56701B1 (sr) 2013-05-17 2018-03-30 Merck Sharp & Dohme Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze
EP3008044B1 (en) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
NO2865735T3 (es) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
KR101809392B1 (ko) 2013-09-27 2017-12-14 머크 샤프 앤드 돔 코포레이션 Hiv 인테그라제 억제제로서 유용한 치환된 퀴놀리진 유도체
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015199167A1 (ja) 2014-06-25 2015-12-30 日本たばこ産業株式会社 置換されたスピロピリド[1,2-a]ピラジン誘導体の製造方法および中間体
JPWO2016027879A1 (ja) 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
WO2016094198A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3285582B1 (en) 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
SI3466490T1 (sl) 2015-04-02 2020-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
EP3377065B1 (en) 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN110062627A (zh) 2016-12-02 2019-07-26 默沙东公司 可用作hiv整合酶抑制剂的三环杂环化合物
EP3752144B1 (en) 2018-02-15 2022-12-28 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CA3101180A1 (en) 2018-04-27 2019-10-31 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
MX2020012185A (es) 2018-05-31 2021-01-29 Shionogi & Co Derivado policiclico de piridona.
EP3801543A4 (en) 2018-06-05 2022-03-02 Merck Sharp & Dohme Corp. HETEROCYCLIC TRICYCLIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
CN108957755B (zh) 2018-07-27 2021-04-30 京东方科技集团股份有限公司 一种显示组件及其控制方法、平视显示器及汽车
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne

Also Published As

Publication number Publication date
KR20210015922A (ko) 2021-02-10
AU2019277548A1 (en) 2021-01-14
PE20210477A1 (es) 2021-03-11
EA202092921A1 (ru) 2021-04-07
CA3102063A1 (en) 2019-12-05
AR115455A1 (es) 2021-01-20
AU2024200783A1 (en) 2024-02-29
ZA202007567B (en) 2022-04-28
AU2019277548B2 (en) 2023-12-14
CL2020003002A1 (es) 2021-04-16
US20210122751A1 (en) 2021-04-29
CN112513042B (zh) 2023-09-29
CR20200644A (es) 2021-02-05
EP3805220A1 (en) 2021-04-14
CR20230571A (es) 2024-01-22
WO2019230858A1 (ja) 2019-12-05
MA52795A (fr) 2021-04-14
EP3805220A4 (en) 2022-01-05
IL279051A (en) 2021-01-31
SG11202011382PA (en) 2020-12-30
PH12020552000A1 (en) 2021-09-27
CN117327072A (zh) 2024-01-02
CO2020014294A2 (es) 2020-12-21
JPWO2019230858A1 (ja) 2021-06-24
CN112513042A (zh) 2021-03-16
EP4257137A2 (en) 2023-10-11
JP7328962B2 (ja) 2023-08-17
US11649236B2 (en) 2023-05-16
JP2023145723A (ja) 2023-10-11
EP4257137A3 (en) 2023-11-01
DOP2020000221A (es) 2021-03-15
BR112020024077A2 (pt) 2021-02-09
US20230227454A1 (en) 2023-07-20
MX2023010377A (es) 2023-09-12

Similar Documents

Publication Publication Date Title
MX2023010377A (es) Derivado policiclico de carbamoilpiridona.
MX2020012185A (es) Derivado policiclico de piridona.
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
UY37623A (es) Derivados de oxadiazol tiofeno fungicidas
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
MX2021006404A (es) Derivados de piridona policiclica sustituida y profarmaco de los mismos.
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
TW200630461A (en) Organic electroluminescent device
KR20180084423A (ko) 디아릴플루오렌 아민 유도체 유기화합물 및 이를 포함하는 유기 전계 발광 소자
MX2019002864A (es) Mezcla aditiva.
MX2021003427A (es) Nuevos oxadiazoles.
CO6420347A2 (es) Derivados de imidazotiazol que tienen estructura de anillo de prolina
CR20200643A (es) Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
UY38906A (es) Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
PH12020500497A1 (en) Compound having cyclic structure
MX2022002878A (es) Compuestos 5,6-heteroaromaticos que contienen bencilaminas utiles contra la infeccion por micobacterias.
SG11201811541TA (en) Composition for removing iron sulfide
PL408406A1 (pl) Zastosowanie związków aryloenonowych
WO2021080280A8 (ko) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
MX2019009935A (es) Alquilacion en alfa de aldehido con una olefina policiclica.
MX2023010453A (es) 2,6,6-trimetil-norpinan-2-ol como una fragancia.
MX2021007276A (es) Compuestos anticancer.
ES393339A1 (es) Un procedimiento para la preparacion de derivados de nafto-quinona.
MX2018004242A (es) Compuestos profragantes y proaromatizantes de peroxihemiacetal.